These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2956870)

  • 21. Long-term oral enoximone therapy in chronic cardiac failure.
    Maskin CS; Weber KT; Janicki JS
    Am J Cardiol; 1987 Aug; 60(5):63C-67C. PubMed ID: 2956871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure.
    Amin DK; Shah PK; Shellock FG; Hulse S; Brandon G; Spangenberg R; Swan HJ
    Am Heart J; 1985 Jan; 109(1):91-8. PubMed ID: 3155585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous use of enoximone.
    Crawford MH
    Am J Cardiol; 1987 Aug; 60(5):42C-45C. PubMed ID: 2956867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential hemodynamic effects of oral enoximone in severe congestive heart failure.
    Murali S; Uretsky BF; Betschart AR; Tokarczyk TR; Kolesar JA; Reddy PS
    Am J Cardiol; 1990 Feb; 65(7):515-9. PubMed ID: 2137668
    [No Abstract]   [Full Text] [Related]  

  • 25. Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure.
    Amin DK; Shah PK; Hulse S; Shellock FG; Swan HJ
    Am Heart J; 1984 Nov; 108(5):1285-92. PubMed ID: 6238513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
    Petein M; Levine TB; Cohn JN
    Circulation; 1986 Mar; 73(3 Pt 2):III230-6. PubMed ID: 3510778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac energetics after intravenous enoximone in idiopathic dilated cardiomyopathy.
    Heiss HW; Hasenfuss G; Holubarsch C; Meinertz T; Just H
    Am J Cardiol; 1987 Aug; 60(5):53C-56C. PubMed ID: 2956869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure.
    Martin JL; Likoff MJ; Janicki JS; Laskey WK; Hirshfeld JW; Weber KT
    J Am Coll Cardiol; 1984 Nov; 4(5):875-83. PubMed ID: 6238075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The electrophysiologic effects of enoximone in patients with preexisting ventricular tachyarrhythmias.
    Miles WM; Heger JJ; Minardo JD; Klein LS; Prystowsky EN; Zipes DP
    Am Heart J; 1989 Jan; 117(1):112-21. PubMed ID: 2521415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative hemodynamic and hormonal response of enoximone and dobutamine in severe congestive heart failure.
    Uretsky BF; Generalovich T; Verbalis JG; Valdes AM; Reddy PS
    Am J Cardiol; 1986 Jul; 58(1):110-6. PubMed ID: 2942027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of enoximone to adrenergic agents in the management of severe heart failure.
    Vincent JL; Léon M; Berré J; Mélot C; Kahn RJ
    Crit Care Med; 1992 Aug; 20(8):1102-6. PubMed ID: 1386567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiischemic and hemodynamic effects of an oral single dose of 150 mg of the phosphodiesterase inhibitor enoximone in patients with coronary artery disease--relation to plasma concentration.
    Mitrovic V; Petrovic O; Bahavar H; Neuzner J; Dieterich HA; Schlepper M
    Cardiovasc Drugs Ther; 1991 Aug; 5(4):689-95. PubMed ID: 1832289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of chronic cardiac insufficiency with intravenous bolus enoximone. Study of a pharmacokinetic-hemodynamic relation].
    Gibelin P; Garraffo R; Sbirrazzuoli V; Lapalus P; Morand P
    Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():75-81. PubMed ID: 2147839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement.
    Shah PK; Amin DK; Hulse S; Shellock F; Swan HJ
    Circulation; 1985 Feb; 71(2):326-31. PubMed ID: 3155500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term therapy of chronic cardiac insufficiency using enoximone].
    Treese N; Erbel R; Rhein S; Diefenbach C; Alken RG; Mohr-Kahaly S; Meyer J
    Dtsch Med Wochenschr; 1987 Jul; 112(30):1163-9. PubMed ID: 2956080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The Western Enoximone Study Group.
    Narahara KA
    Am Heart J; 1991 May; 121(5):1471-9. PubMed ID: 1826806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance.
    Crawford MH; Richards KL; Sodums MT; Kennedy GT
    Am J Cardiol; 1984 Apr; 53(8):1051-3. PubMed ID: 6230926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central and regional hemodynamic effects of oral enoximone in congestive heart failure: a double-blind, placebo-controlled study.
    Leier CV; Lima JJ; Meiler SE; Unverferth DV
    Am Heart J; 1988 May; 115(5):1051-9. PubMed ID: 2966546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute effects of enoximone in chronic heart failure.
    Saborowski F; Peters P; Schneider M; Fehske W; Dieterich HA
    J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S57-61. PubMed ID: 2480487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Enoximone, vasodilator and/or inotropic agent in congestive cardiac insufficiency? Hemodynamic and ventriculographic study of 20 cases].
    Durrieu C; Rochoux G; Coste P; Le Goff G; Besse P
    Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():43-50. PubMed ID: 2147834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.